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The high prevalence of Japanese cedar pollinosis in Japan is associated with a negative impact on the
quality of life of patients, as well as signiﬁcant loss of productivity among the workforce in early spring,
thus representing a serious social problem. Furthermore, the prevalence is increasing, and has risen by
more than 10% in this decade. Cry j 1 and Cry j 2 were identiﬁed as the major allergens in Japanese cedar
pollen (JCP), and in 2004, the existence of other major and minor allergens were revealed by a combi-
nation of two-dimensional electrophoresis and immunoblotting analysis. Allergenome analysis identiﬁed
a chitinase, a lipid transfer protein, a serine protease, and an aspartic protease as novel IgE-reactive
allergens in patients with JCP allergy. Thaumatin-like protein (Cry j 3) was shown to be homologous
to Jun a 3, a major allergen from mountain cedar pollen. Isoﬂavone reductase-like protein was also
characterized in a study of a JCP cDNA library. The characterization of component allergens is required to
clarify the sensitizer or cross-reactive elicitor allergens for component-resolved diagnosis (CRD).
Increasing evidence from numerous clinical trials indicates that CRD can be used to design effective
allergen-speciﬁc immunotherapy. In this review, we summarize the eight characterized JCP allergens and
discuss the impact of CRD and characterization of novel allergens on allergen-speciﬁc immunotherapy.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Prevalence of Japanese cedar pollinosis in Japan
Japanese cedar (Cryptomeria japonica) pollinosis is one of the
most prevalent forms of seasonal rhinitis in Japan. Japanese cedar
pollen (JCP) is released from the male ﬂowers of Japanese cedar
trees and levels are usually high from February to April in Japan.
During this period, the forecasted levels of JCP in each Japanese
geographic prefecture are broadcast with weather reports on a
daily basis, and many people choose to wear face masks when theylar Biotechnology, Graduate
niversity, 1-3-1 Kagamiyama,
ry for Vaccine Design, RIKEN
e Institute of Physical and
, Yokohama, Kanagawa 230-
jimura), skawa@hiroshima-u.
ety of Allergology.
rgology. Production and hosting by Elseventure outside.1 Despite the high prevalence of pollinosis and
huge interest in the conditions of JCP dispersal in recent decades,
pollinosis was ﬁrst reported in Japan in 1961 as an allergy to
ragweed pollen.2 Subsequently, Japanese cedar pollinosis was
discovered in the Nikko area of Tochigi prefecture in 1964.3 In the
past half-century, JCP levels and the prevalence of pollinosis have
increased dramatically.4 The results of a nationwide survey in 2001
using cross-sectional random sampling methods showed that the
estimated prevalence of Japanese cedar pollinosis was 13.1%.5 The
most recent survey conducted in 2008 revealed that the prevalence
of pollinosis in the Japanese population had almost doubled to
26.5%.6 Pollinosis has a negative impact on quality of life7; there-
fore, the recent increase in the prevalence of Japanese cedar polli-
nosis represents a signiﬁcant social problem in Japan.
Japanese cedar and cypress are major constituents of Tax-
odiaceae family in Japan. Mountain red cedar, European cypress,
and Rocky mountain junipers in Mediterranean countries and
United States are also members of Taxodiaceae and Cupressaceae
family.8e11 Patients allergic to pollen from a member of Tax-
odiaceae/Cupressaceae family shows allergic symptoms aftervier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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3 allergens from pollen in the family cross-react among the polli-
nosis patients.
Sensitization with pollen allergens
Pollinosis is triggered by the invasion of the nasal and ocular
mucosa by pollen grains. Many allergens with the capacity to bind
immunoglobulin E (IgE) have been identiﬁed from many plant
species and are registered on allergen databases.12 Some pollen-
derived allergens are species-speciﬁc, while others are commonly
identiﬁed in various plant species as enzymes or components of
grasses, trees, vegetables, and fruits; these are known as pan-
allergens. Pollen grains readily access the aqueous phase of the
nasal and ocularmucosal membranes, where they are hydrated. The
hydrated pollen grain ruptures, releasing their cytoplasmic com-
ponents, including allergens, non-allergenic proteins, starch gran-
ules, and certain chemicals.13 Non-proteinous components, such as
pollen cytoplasmic granules and pollen-associated lipid mediators,
may act as adjuvants in the induction of antigen-speciﬁc type II
helper T cell (Th2)-skewing immune responses to cytoplasmic and
surface proteins of pollen during the sensitization phase.14e16 Some
proteins also act as adjuvants in the induction of Th2 responses,
accumulation of inﬂammatory cells, and activation of innate im-
mune cells. Pollen contains proteases in its cytoplasm; this class of
enzymes has recently been reported to be important adjuvants of
innate and adaptive immune responses via alarm cytokine (alarmin)
signals. Serine and cysteine proteases, including papain, stimulate
epithelial cells at the mucosal surface and induce the release of
thymic stromal lymphopoietin (TSLP) via protease-activated re-
ceptor 2 (PAR2) activation. TSLP is expressed mainly by endothelial
cells and keratinocytes, and its expression is promoted by IgE, Th2Fig. 1. Schematic hypothetical model of sensitization with Japanese cedar pollen. Pollen p
duction of cytokines such as IL-33, which in turn induces the migration and activation of inﬂ
cells induce naïve T cells to differentiate into Th2 cells following TCR stimulation by antigen-
class-switch recombination of B cells to IgE-producing B cells and plasma cells. The antigen
cross tight junctions and bind to corresponding antigen-speciﬁc IgE, causing the release of in
transfer protein; IFR, isoﬂavone reductase-like protein; TSLP, thymic stromal lymphopoietin
cell; ECP, eosinophil cationic protein; MBP, major basic protein; Tfh, follicular helper T cell.cytokines including interleukin (IL)-4 and IL-13, and alarmins
including IL-25 and IL-33.17 TSLP can activate myeloid-derived
dendritic cells (mDC), which then prime CD4þ T cells to differen-
tiate into antigen-speciﬁc Th2 cells in a process orchestrated by
OX40-OX40L interactions. Furthermore, TSLP can directly activate
naïve CD4þ Tcells to promote proliferation and differentiation to the
Th2 phenotype through induction of IL-4 following T cell receptor
(TCR) stimulation.18 Protease-stimulated epithelial cells also secrete
alarmins with or without the induction of necrosis.19,20 IL-25, IL-33,
and TSLP can activate innate immune cells in a process orchestrated
by other cytokines in different manners; IL-25 alone induces in-
ﬂammatory group 2 innate lymphoid cells (iILC2), while natural
helper (NH) cells are strongly activated by a combination of IL-25
and IL-2. A combination of IL-25 and IL-33 induces and activates
group 2 innate lymphoid cells (ILC2), while IL-33 alone increases NH
cell numbers.21 Activated ILC2 secrete large amounts of IL-5 and IL-
13,which promote the differentiation and activation of naïve CD4þ T
cells into Th2 cells and inﬂammatory effector cells.22 These reports
strongly suggest that pollen contains proallergic natural adjuvants
provoking type 2 immunity during the sensitization and elicitation
phases of pollinosis (Fig. 1).
In addition to mucosal sensitization, the transcutaneous route
may also be important for sensitization in dermatitis and food al-
lergy. In Japan, people who use facial soap containing hydrated
wheat protein on a daily basis can develop wheat-dependent ex-
ercise-induced anaphylaxis (WDEAI) after the ingestion of wheat-
containing food. These patients react mainly to g-gliadin and
u1.2-gliadin fromhydratedwheat protein contained in the product,
while patients diagnosed with conventional wheat protein-
dependent WDE without using the product react strongly to u5-
gliadin. The patients with hydrated wheat protein-WDEAI sensi-
tized by the soup showed more severe systemic allergic reactionsrotease-mediated damage to the epithelial cells of the nasal mucosa induces the pro-
ammatory cells and innate lymphoid cells. Th2 cytokines from ILC2 and inﬂammatory
presenting cells. The antigen-speciﬁc Th2 cells and follicular helper T cells (Tfh) induce
-speciﬁc IgE binds to FcεRI receptors on mast cell and basophils. Allergens from pollen
ﬂammatory mediators, such as histamine and leukotrienes from effector cells. LTP, lipid
; DC, dendritic cell; Th0, naïve T cell; LTs, leukotrienes; ILC2, group 2 innate lymphoid
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tients after ingestion of natural wheat product.23
These forms of type I allergy are the result of antigen-
sensitization following disruption of epithelial cells by physical,
enzymatic, and chemical stimuli. Pollen extract shows serine and/
or cysteine endopeptidase activity although the content and
releasability of the proteases differed according to the plant fam-
ilies.24 Disruption of skin barrier by pollen-derived proteases may
contribute to sensitization by pollen especially in peak pollen
season. Many atopic dermatitis patients shows symptom ﬂare in
peak pollen season for Japanese cedar and cypress in Japan. This
symptom ﬂare in the peak pollen season occurs independently on
symptoms for the pollinosis.25 Pollen encountered damaged skin
barrier invoke inﬂammation and may contribute to epicutaneous
sensitization of pollen-derived allergens.
Japanese cedar pollen allergens
The full spectrum of allergens from JCP reacted with IgE in
plasma samples obtained from patients with Japanese cedar polli-
nosis was analyzed using two-dimensional (2-D) sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
immunoblotting methods. This kind of comprehensive omics
analysis of component allergens combined 2-D immunoblotting
with subsequent protein identiﬁcation by protein sequencing or
mass spectrometry is known as allergenome or allergome analysis.
Allergenomic analysis showed at least 131 individual spots had
capacity to react with IgE in the plasma of patients with allergies to
JCP.26 To date, eight allergens have been isolated and their biolog-
ical properties characterized (Table 1). Allergens are formally
named using the systematic nomenclature of the Allergen
Nomenclature Sub-Committee of the World Health Organization
and International Union of Immunological Societies. The system
uses the ﬁrst three letters of a genus, a single letter for the species,
and a number that refers to the chronological order of allergen
puriﬁcation and sometimes to the properties of the allergens.27
Therefore, the registered allergens from JCP are designated “Cry j”
from the genus Cryptomeria and the species japonica, which is the
botanical name for Japanese cedar.
Cry j 1 is major component of JCP extract and most patients
suffered from Japanese cedar pollinosis have speciﬁc IgG and IgE toTable 1
Identiﬁed allergens from Japanese cedar pollen.
Name in
original paper
Biological or perspective
function
Molecular weight
(SDS-PAGE, kDa)
Cry j 1 Pectate lyase 45-50
Cry j 2 Polygalacturonase 37 (non-reduced)
45 (reduced)
Cry j 3 Thaumatin-like protein 19 (non-reduced)
27 (reduced)
CJP-4 Class IV chitinase 34
CJP-6 Isoﬂavone reductase-like 34 (recombinant)
CJP-8 Lipid transfer protein 20 (recombinant)
CPA9 Subtilisin-like serine protease 90
CPA63 Aspartic protease 52 (recombinant, proenzyme)
42 (mature enzyme)Cry j 1. Allergenomic analysis of JCP showed Cry j 1 had highest IgE-
binding frequency with patients allergic to JCP and 31 spots had
higher IgE-binding capacity than that of an Cry j 2 isoform.26 Some
new JCP antigen spots were characterized as additional major al-
lergens that have comparable IgE-binding frequency with that of
Cry j 2. The IgE-binding frequency of some allergens in JCP
including Cry j 1 and Cry j 2 may be underestimated on 2-D
immunoblot because some conformational epitopes are not sta-
ble for heat, high and low pH condition, and denature by chemicals.
It will be important to quantify the amount of each allergen in JCP
and to evaluate the allergenicity by measurement of IgE reactivity
or intradermal injection test using each native allergen for clarify
the clinical importance of each allergen. As we pointed out above,
JCP contains potential important allergen molecules other than Cry
j 1 and Cry j 2. Those new JCP allergens cross-react with other plant
allergens, and show sequence identity with other causative aller-
gens identiﬁed in food allergy and pollinosis. Below we summarize
the eight JCP allergen molecules identiﬁed thus far (Table 1).
Cry j 1: pectate lyase
Cry j 1, the ﬁrst allergen isolated from JCP, was originally re-
ported as sugi basic protein (SBP; Sugi means Japanese cedar in
Japanese) in 1983,28 and is a major component of JCP extract;
approximately 35mg per 100 g pollen is routinely extracted.29 Cry j
1 is a basic glycoprotein homologous to pectate lyase and has a
molecular weight of 45e51 kDawith a pI 8.9 to 9.2.30 It is one of the
major causative allergens for Japanese cedar pollinosis and its IgE-
binding frequency is reported to be 86% (12/14) by enzyme-linked
immunosorbent assay (ELISA) and 51% (35/68) by immunoblot
analysis.31,32 Most IgE-binding epitopes in Cry j 1 are reported to be
conformational epitopes and heat-labile.28,33 Cry j 1 exists as
several isoforms in JCP that differ in their primary sequences and
post-translational modiﬁcation with oligosaccharides.30 Three po-
tential N-glycosylation sites exist in Cry j 1, and Asn-170 and Asn-
333 were found to carry asparagine-linked oligosaccharides.34 In
allergenomic analysis, at least 12 Cry j 1 isoforms were fractionated
on 2-D SDS-PAGE, with IgE-binding reactivity ranging from 27.5% to
75%.26,35 The Japanese Society of Allergology standardized JCP
extract as vaccines for allergen-speciﬁc immunotherapy (SIT) and
the measurement of Cry j 1 content has been used as the in vitroAccession number(s) on DNA data
bank of Japan (DDBJ)
Homologous allergens
D34639,
D26544 (Cry j IA), D26545 (Cry j IB),
AB081309 (Cry j 1.1), AB081310 (Cry j 1.2)
Cha o 1 (Japanese cypress)
Cup a 1 (Arizona cypress)
Jun a 1 (Mountain cedar)
Jun v 1 (Eastern red cedar)
D37765, D29772, E09607, E10716,
AB081403 (Cry j 2.1), AB081404(Cry j 2.2),
AB081405 (Cry j 2.3)
Cha o 2 (Japanese cypress)
Cup a 2 (Arizona cypress)
Jun a 2 (Mountain cedar)
Jun v 2 (Eastern red cedar)
AB081303 (Cry j 3.1), AB081304 (Cry j 3.2),
AB081305 (Cry j 3.3), AB186384 (Cry j 3.4),
AB186385 (Cry j 3.5), AB186386 (Cry j 3.6),
AB212218 (Cry j 3.7), AB254807 (Cry j 3.8)
Jun a 3 (Mountain cedar)
Jun v 3 (Eastern red cedar)
Mal d 2 (Apple)
Pru av 2 (Cherry)
AB196451 Pers a 1 (Avocado)
Cas s 5 (Chestnut)
Mus a 1 (Banana)
AY028631 Bet v 5 (Birch), Pyr c 5 (Pear)
AB520844 Pru p 3 (Peach), Mal d 3 (Apple),
Fra a 3 (Strawberry)
Not registered Cuc m 1 (Melon)
AB510538 Not reported
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Pectate lyase is a common component in several species of plant
pollens; therefore, the Cry j 1-speciﬁc IgE have the potential to
cross-react with other pectate lyase allergens from tree pollens
such as Chao 1 (78% sequence identity with Cry j 1), Bet v 1 (20%),
Car b 1 (14%), and Aln g 1 (18%) from Japanese cypress (Chamae-
cyparis obtusa), birch (Betula verrucosa), hornbeam (Carpinus
betulus), and alder (Alnus glutinosa), respectively.8
Cry j 2: polygalacturonase
Cry j 2, which was the second allergen isolated from JCP, was
also reported to be a major allergen,31 with 2.9e14 mg extracted
per 100 g pollen, depending on the extraction method (29 and
unpublished data). Cry j 2 is a basic protein homologous to poly-
galacturonase, with a molecular weight of 45 kDa under reduced
conditions.31,38 Its IgE-binding frequency is reported to be 71% (10/
14) by ELISA and 47% (32/68) by immunoblot analysis.31,32 Cry j 2
has one potential N-glycosylation site, although its actual glyco-
sylation remains to be conﬁrmed. Allergenomic analysis revealed at
least three Cry j 2 isoforms with different isoelectric points. There
was no marked difference in the IgE-binding reactivity among the
different isoforms (range 32.5%e40%) in Japanese cedar pollinosis
patients.26 Cry j 2-speciﬁc IgE showed cross-reactivity with Chao 2
(74% sequence identity with Cry j 2), another polygalacturonase
allergen from Japanese cypress pollen.39
Cry j 3: thaumatin-like protein
Cry j 3, which was isolated from a cDNA library derived from JCP,
is a homologue of Jun a 3, a major allergen from mountain cedar
(Juniperus ashei) pollen.40 Clones encoding Cry j 3 were isolated
from Cry j 3.1 to Cry j 3.6.41 Native Cry j 3 was isolated from JCP
using multi-dimensional chromatography, and the corresponding
clone was designated Cry j 3.8.42 Native Cry j 3 is glycoprotein with
a molecular weight of 27 kDa under reduced conditions and the
IgE-binding frequency is 27% (27/100) by ELISA. Cross-reactivity
between Cry j 3 and Jun a 3 (86% sequence identity with Cry j
3.8) was expected because three sequential epitopes of Jun a 3 are
highly conserved in Cry j 3.8, with identities of 92%, 100%, and 86%.
Rabbit antiserum raised against Jun a 3 recognized Cry j 3.42,43 Cry j
3 is a homologous allergen to thaumatin-like proteins (TLPs) and
belongs to the pathogenesis-related-5 (PR-5) group family. Thau-
matin is an intensely sweet protein that is isolated from the fruits of
a West African rain forest shrub (Thaumatococcus daniellii) and is
induced in response to infections by pathogens and environmental
factors.44 PR family proteins are reported as plant pan-allergens.
Cry j 3 is also homologous to other PR-5 member allergens such
as Mal d 2 (45%), Pru av 2 (44%), Act d 2 (50%), and Cap a 1 (47%)
from apple (Malus domestica), sweet cherry (Prunus avium), kiwi
fruit (Actinidia deliciosa), and bell pepper (Capsicum annuum),
respectively. Cry j 3 is implicated in cross-reactivity between al-
lergies to JCP and tomato (Solanum lycopersicum) because two
isoforms of TLP (NP24, 44%) are isolated from tomato fruit.45,46
Therefore, it can be speculated that Cry j 3 is important in oral al-
lergy syndrome (OAS) among patients with Japanese cedar polli-
nosis and allergies to fruit and vegetables.
CJP-4: class IV chitinase
CJP-4 is a class IV chitinase identiﬁed in allergenomic analysis of
JCP.47 It is a 34-kDa protein with endochitinase activity. The IgE-
binding frequency of CJP-4 is comparable with that of Cry j 1,
although the amount of CJP-4 is much less than that of Cry j 1. CJP-4
is a class IV chitinase categorized into family 19 chitinases, whichpossess two consensus family 19 signature motifs in the catalytic
domain, in addition to the chitin-binding motif in the hevein
domain. Endogenous acidic mammalian chitinase was reported to
exacerbate Th2 inﬂammation and airway responsiveness, in part by
accelerating IL-13 pathway activation and chemokine induction.48
Exogenous pollinic chitinase may also have the potential to
participate in these physiological functions to enhance Th2 re-
sponses against JCP allergens. CJP-4 is a member of the PR-3 family
and is homologous to PR-3 allergens, such as Hev b 11 (38.4%
sequence identity with CJP-4), Pers a 1 (38.2%), Cas s 5 (38.1%), and
Mus a 1 (41.5%) from latex (Hevea brasiliensis), avocado (Persea
americana), chestnut (Castanea sativa), and banana (Musa acumi-
nata), respectively. CJP-4 has a highly conserved chitin-binding
motif and a hevein-like domain responsible for the cross-
reactivity in latex-fruit syndrome. CJP-4 cross-reacts with IgE
from patients allergic to latex and inhibits binding between the
latex extract and the IgE. Therefore, CJP-4 may be important as a
cross-reactive allergen in latex-fruit syndrome.
CJP-6: isoﬂavone reductase-like protein
CJP-6 was cloned as an isoﬂavone reductase-like allergen from a
JCP cDNA library. Native (n)CJP-6 has not been isolated and its
immunological properties remain to be elucidated; however, re-
combinant (r)CJP-6 exhibited 76% IgE-binding frequency (19/25) in
Cry j 1-positive patients with Japanese cedar pollinosis.49 CJP-6 is
homologous to other members of the isoﬂavone reductase family,
such as Bet v 5 (61% sequence identity with CJP-6) and Pyr c 5 (60%)
from birch and pear (Pyrus communis), respectively; therefore, it is
also important to test whether the CJP-6 molecule shows IgE cross-
reactivity with isoﬂavone reductase counterparts from other pol-
lens and plant-based foods.
CJP-8: lipid transfer protein homologue
The other allergens, CJP-8, CPA9, and CPA63 were also identiﬁed
in the allergenome analysis. CJP-8 is homologous to lipid transfer
protein (LTP).50 Although nCJP-8 has not been isolated, rCJP-8
exhibited 37.5% IgE-binding frequency (6/16) in patients with Jap-
anese cedar pollinosis. The LTP allergens, rPar j 1 (11% sequence
identity with CJP-8) from pellitory (Parietaria judaica) and rPru p 3
(15%) from peach (Prunus persica), inhibited the binding between
rCJP8 and rCJP8-positive JCP-allergic plasma IgE, indicating that
CJP8 is also a pan-allergen for OAS.
CPA9: subtilisin-like serine protease
CPA9 is a plant subtilisin-like serine protease and nCPA9 reacted
with 88.5% (23/26) of patients allergic to JCP in ELISA.51 Serine
proteases are known as house dust mite (Dermatophagoides farinae
and D. pteronyssinus) allergens and three classes have been re-
ported as allergens; group 3 (trypsin), group 6 (chymotrypsin), and
group 9 (collagenase). Serine protease allergens, Pen ch 13 (alkaline
serine protease) and Pen ch 18 (vacuolar serine protease), are also
reported in allergenic fungi (Penicillium chrysogenum). CPA9 is ho-
mologous to Cuc m 1 (40% sequence identity with CPA9) in musk-
melon (Cucumis melo) and melon extract inhibits binding between
nCPA9 and CPA9-speciﬁc IgE. Therefore, CPA9 is also implicated as a
pan-allergen for OAS.
CPA63: aspartic protease
CPA63 structurally belongs to atypical type of plant aspartic
protease family members that shows proteolytic activity under
acidic conditions.52 rCPA63 was shown to react with IgE from 58%
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a 52-kDa proenzyme of a 42-kDa mature enzyme generated by
autolysis. nCPA63 appeared as a 42-kDa protein in 2-D SDS-PAGE,
demonstrating that nCPA63 is present in the mature form in JCP.
Another aspartic protease allergen, Bla g 2, was identiﬁed in the
German cockroach (Blattella germanica).
Impact of component-resolved diagnosis on Japanese cedar
pollinosis
It will be important to analyze the IgE-binding reactivity and
intensity to group 1 and 2 major allergens in cedar/cypress species
and pan allergens for plant-fruit syndrome to discriminate Japa-
nese cedar pollinosis, other cypress/juniper pollinosis, and OAS. It is
necessary to conﬁrm strong IgE reactivity with Cry j 1 and Cry j 2
and weak or negative reactivity with major allergens from other
cypress and juniper to conclude that patients are sensitized to
Japanese cedar pollen. Strong IgE-reaction with CJP-4, CJP-6, CJP-8,
or CPA9 may suggest that patients would be suffered OAS rather
than Japanese cedar pollinosis. Further information will be neces-
sary to achieve more accurate diagnosis for Japanese cedar polli-
nosis by component-resolved diagnosis (CRD).
Allergen-speciﬁc immunotherapy
Allergen-speciﬁc immunotherapy (SIT) is considered to be the
only curative intervention associated with changes of the natural
course of IgE-dependent type I allergy. The ﬁrst report of SIT
involved injection immunotherapy for hay fever without an adju-
vant in 1911.53 During the century that followed, the protocol for SIT
has improved to increase efﬁcacy and safety through coadminis-
tration of allergens with immunostimulatory adjuvants, premed-
ication with anti-histamine or anti-human IgE antibodies, or
administration of allergens via alternative routes.54 Over the last
two decades, sublingual SIT (SLIT) has become recognized as a
preferable form of immunotherapy compared with conventional
subcutaneous SIT (SCIT) in terms of safety, feasibility, and conve-
nience for patients.55
Crude extracts from natural allergen sources have been used as
SIT vaccines widely in the clinics. The World Allergy Organization
recommends that standardized vaccines should be used for SIT if
they are available.56 Over the last 20 years, many suppliers have
standardized their allergen extracts based on the concentration of
major allergens or bioactivity in intradermal injection tests using
individual in-house reference materials. However, due to differ-
ences in the protocols and methods for standardization of allergen
extracts used by different suppliers, it is still difﬁcult to compare
the therapeutic effects and safety among clinical trials involving
different allergen extracts. It has been proposed that vaccines
should be standardized using a protocol based on mass units of
major allergens and that the active ingredients of the treatment
should be quantiﬁed. Isolation and characterization of component
allergens in allergen sources is still an important issue for the
purposes of quantifying the active ingredients in an extract.
Polyclonal IgE antibodies from an allergic patient react with
many allergens in a single allergen source and the proﬁles or IgE-
reactive allergens differ among individuals. In the allergenome
study of JCP, the average number of IgE-reactive spots in 40
symptomatic patients with JCP allergy was 37 ± 22 (range, 4e86)
spots. Among these patients, 45% (18/40) showed IgE-binding
spectra including reactivity (34 ± 17 spots) with many allergens
other than themajor allergens, Cry j 1 and Cry j 2. A further 25% (10/
40) showed spectra that were predominantly the result of reactivity
with the major allergens (34 ± 14 spots). In addition, 17.5% (7/40)
showed strong reactivity with numerous allergens including themajor allergens (63 ± 15 spots) and ﬁnally 12.5% (5/49) showed
weak reactivity with a few allergens (6 ± 1 spots).26 This report did
not include details of OAS status; however, all patients showed a
positive RAST score for JCP (RAST score 2) and would be candi-
dates for SIT using JCP extract. These differences in IgE-spectra
among individuals may represent the basis of an approach to
distinguish good and poor responders for SIT.
Two years of SLIT treatment for Japanese cedar pollinosis
signiﬁcantly ameliorated nasal and ocular symptoms and reduced
the requirement formedicines in the second year; this amelioration
was sustained 1 year after termination of the treatment. This report
implicated induced regulatory T cells (deﬁned as a IL-10þ Foxp3þ T
cells in the population of CD25þ CD4þ leukocytes) as biomarkers
for monitoring the response to SIT, and furthermore, indicated that
the ratio of speciﬁc IgE to total IgE may be a candidate predictive
biomarker to distinguish good and poor responders prior to treat-
ment.57 Thus, it can be speculated that a combination of IgE-
binding allergen proﬁling and the ratio of speciﬁc IgE to total IgE
may be a good predictive biomarker of the efﬁcacy of SIT.
Impacts of component-resolved diagnosis on allergen-speciﬁc
immunotherapy
SIT is an antigen-speciﬁc treatment; therefore, accurate diag-
nosis is highly important.58 Accurate elucidation of the sensitizing
allergen source for individual patients is a ﬁrst step to achieving
effective immunotherapy, although allergic patients are often pol-
ysensitized with pollens from many plant species and other sour-
ces, including vegetables, fruits, mites, fungi, and animals.
Discrimination of pollinosis and food allergy, especially allergy to
vegetables and fruits, is important to determine allergens for SIT.
CRD is a powerful method for the determination of the sensitizing
allergen source. Simultaneous analysis of IgE reactivity with aller-
gens, including major allergens from various pollen species and
pan-allergens such as non-speciﬁc lipid transfer protein and pro-
ﬁlin is necessary to discriminate pollinosis from OAS.59 Construc-
tion of a database of patterns of IgE-reactive allergens and
variations in sensitizing allergen sources in various geographic
areas may be useful for such discrimination and selection of aller-
gens for SIT in the clinic.
This kind of serological approach using plasma IgE is usually
easy, low-cost, and safe compared with in vivo allergen provocation
tests; however, IgE serology is not always a sensitive predictor of
allergenic activity and clinical relevance. A study that compared the
IgE reactivity to recombinant component allergens from timothy
(Phleum pratense) and birch with skin reactivity showed a strong
association between a positive skin reaction and the presence of
allergen-speciﬁc IgE, although the correlation with allergen-
speciﬁc IgE levels was weak.60 Native allergens contain various
isoforms with minor sequence variations or post-translational
modiﬁcations, and these differences may alter the IgE-binding ca-
pacity of each isoform.26,61 Therefore, the recombinant allergens to
be used for in vitro or in vivo diagnosis should contain most of the
IgE epitopes present in natural allergens.
Selection of patients and allergens for allergen-speciﬁc
immunotherapy
CRD also has an impact on exclusion of patients from SIT. A
subpopulation of patients who report symptoms of pollinosis were
originally sensitized with plant foods and have speciﬁc IgE that
react strongly with pan-allergens but weakly with the major pollen
allergens. The application of CRD to select appropriate patients for
SIT is called CRD-based immunotherapy (CRD-IT). In a study con-
ducted in 651 children with moderate-to-severe pollen-related
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prick test (SPT) reactions against clinically relevant sensitization
with grass (P. pratense), olive (Olea europaea), and pellitory pollen
extracts, respectively, did not show IgE reactivity with the major
allergens Phl p 1, Phl p 5, Ole e 1, or Par j 2. In the case of birch and
mugwort (Artemisia vulgaris) pollinosis, more than 50% of the pa-
tients with positive SPT reactions against each extract showed
negative IgE reactivity to Bet v 1 and Art v 1, respectively. The
populationwith inconsistencies between the results of SPTand CRD
showed IgE sensitization to proﬁlin (Phl p 12) or polcalcin (Phl p 7),
although this was not true for all patients. This study showed that
among 508 of the 651 patients who would have received an SIT
prescription when evaluated only on the basis of clinical history,
pollen calendars, and SPT responses, 170 (33%) would have received
SIT with a different composition, and a further 52 (10%) would have
received no SIT at all.62 CRD also reveals a mismatch or over/un-
derpowered immunization by extract for SIT. A SIT study using an
allergen cocktail for P. pratense (Phl p 1, Phl p 2, Phl p 5, and Phl p 6)
classiﬁed patients into four categories based on the patient's proﬁle
IgE reactivity with the allergens. Among the 176 patients included,
only 4% were matched for IgE proﬁle and components of the
extract; of those showing the same proﬁle between IgE-reactive
allergens and the components of the extract. Among the patients,
29% were underpowered; with a greater number of IgE-reactive
allergens than the number of components. A further 32% were
overpowered; with fewer IgE-reactive allergens than the number of
components. In addition, 32% were over/underpowered; with
greater numbers of IgE-reactive allergens than the number of
components and the extract contained allergens to which the pa-
tient was not sensitized, and ﬁnally 3% were completely mis-
matched.63 Therefore, CRD is considered to be useful for precise
selection of an allergen source or allergen cocktails for effective SIT;
however, further clinical investigations are required to verify the
beneﬁt of CRD-IT in achieving more effective SIT compared with
classical SIT based on a clinical history, positive IgE reactions to
whole extracts, and positive SPT reactions.
Prediction of adverse events by component-resolved diagnosis
The use of CRD in SIT may also be valuable in predicting the
occurrence of adverse events in SLIT. These are usually very mild
and involve local reactions such as itching and swelling of the oral
mucosa,64 which may be triggered partially by pan-allergens for
latex-fruit syndrome and OAS, such as chitinase and LTP, contained
in pollen extracts.47,65 Patients exhibiting strong IgE reactivity with
these pan-allergens are likely to show local side-effects induced by
pollen SLIT, and the CRD proﬁle may be useful in predicting local or
gastrointestinal side-effects as a result of SLIT using whole-pollen
extract.
Therapeutic effects of allergen-speciﬁc immunotherapy on
reactions to homologous plant species
Many allergens commonly contained in plants show IgE cross-
reactivity and the eliciting allergen is sometimes different from
the original sensitizing allergen source. This type of cross-reactivity
observed in B cell epitopes reﬂects a repertoire of immunoglobulin
speciﬁcity. Such cross-reactivity in T cell recognitions remains to be
elucidated and the differences in T cell recognition among homol-
ogous allergens may lead to the differences in the therapeutic ef-
fects of SIT. SIT using JCP extract did not improve the clinical
symptoms of Japanese cypress pollinosis, although the amino acid
sequences of the major Japanese cedar allergens are highly ho-
mologous to those from cypress.66 Another report also indicated
poor clinical responses to SIT using short ragweed (Ambrosiaartemisiifolia) pollen extract for giant ragweed (A. triﬁda) pollinosis
patients, and vice versa.67 In a case of OAS, SIT using birch pollen
extract was not effective for already established apple allergy,
although the major allergens, Bet v 1 in birch and Mal d 1 in apple,
show 64% identity at the amino acid level.68 Very small differences
in amino acid sequences lead to distinct T cell responses and may
affect the induction of T cell tolerance or regulatory T cells by SIT.69
Thus, the geographic situation and species of scattering pollen
should be considered carefully in the selection of allergens for SIT.
Personalized allergen-speciﬁc immunotherapy
CRD facilitates proﬁling of IgE-reactive allergens for individuals.
It is theoretically possible to personalize the extract used for SIT
such that it contains only allergens to which the patient is sensi-
tized; this is known as personalized medicine or tailor-made
therapy.70 However, in practice, this requires the preparation of
an extract containing every component as a recombinant or a pu-
riﬁed native allergen in a process that complies with good
manufacturing practice suitable for medical use. Consequently, this
approach has poor feasibility in terms of practicality, cost, and
solubility of the recombinant proteins. Depending on the allergen
source, it may be possible to achieve clinical efﬁcacy using one
major allergen that is comparable with that achieved using a whole
extract. A clinical trial of SCIT with pullulan-conjugated Cry j 1 for
Japanese cedar pollinosis showed that the improvement in clinical
symptoms after pullulan-Cry j 1 administration was comparable
with that observed in response to the whole-pollen extract, with
fewer adverse events.71 This effect was also observed for patients
with birch pollinosis. In a study using rBet v 1, nBet v 1, birch pollen
extract, and placebo for SIT, signiﬁcant reductions in rhino-
conjunctivitis scores, rescue medication scores, and skin sensitiv-
ities were observed in the rBet v 1, nBet v 1, and extract groups
compared with the placebo group, and the degree of improvement
was comparable among the three actively treated groups.72 The
number of allergens included in a SIT vaccine to achieve a thera-
peutic effect comparable with that achieved with an extract may
differ among species of allergen sources. For instance, it appears
that there are fewer allergens from tree pollen than from grass
pollen.60 The proﬁle of IgE-reactive allergens for tree is apparently
uncomplicated and comprises predominantly group 1 and 2 major
allergens; it can be speculated that this accounts for the achieve-
ment of comparable clinical improvement using a single major
allergen in SIT to that achieved with whole extract from Japanese
cedar and birch pollen. Grass pollen contains a large number of IgE-
reactive major allergens, therefore, only one or a combination of a
few allergens may not be enough to achieve clinical improvement
comparable with that achieved with the whole extract.
De novo sensitization during SIT is also an important issue in
considering the advantage of CRD-IT. It will be very difﬁcult to
distinguish whether de novo sensitization occurred during SIT
treatment or by natural exposure to allergens. In a study of suc-
cessful rush SCIT for up to 3 years in patients of birch pollinosis, 17
of 26 patients (65%) showed new IgE speciﬁcities after SCIT
compared with those detected before SCIT based on immunoblot
analysis. This new sensitization was observed during the early
phase of rush SCIT including during the ﬁrst birch season in three of
the patients, while no patients without SCIT showed new IgE
sensitization during the study.73 A study of SCIT for timothy grass
pollinosis also showed de novo sensitization to allergens that were
not recognized before treatment on the basis of Pharmacia CAP
analysis. During SIT in a total of eight patients, one showed de novo
sensitization to Phl p 4 and Phl p 6, while another was transiently
sensitized to Phl p 4.74 These reports showed a risk of de novo
sensitization by SIT using a natural extract. However, a study of
Fig. 2. Theoretical models of the mechanism by which IgG suppresses the activation of Th2 or inﬂammatory cells during allergen-speciﬁc immunotherapy (SIT). a) IgG or IgG4,
which recognize the same epitope as IgE, prevent binding of IgE and the invading allergen. The blocking IgG antibody prevents allergen binding to IgE on the surface of mast cells. b)
IgG or IgG4, which recognize the same epitope as IgE, bind to allergens preventing the formation of immunocomplexes between allergens and IgE, and prevent subsequent IgE-
facilitated antigen presentation (FAP; IgE-mediated uptake by antigen-presenting cells). The blocking IgG prevents FAP by blocking the binding of immunocomplex with CD23
(FcεRII) on B cells, and with CD23 and FcεRI on dendritic cells. c) A subtype of IgG, which recognizes an epitope distinct from that bound by IgE, binds allergen independently to form
immunocomplexes consisting of IgG, IgE, and allergen. The IgG bound to the allergen binds to suppressive Fcg receptors, such as FcgRIIb, and inhibits activation signals from FcεRI.
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not show de novo sensitization to new components, including rPhl
p 1, rPhl p 2, nPhl p 4, rPhl p 5, rPhl p 6, rPhl p 7, rPhl p 11, or rPhl p
12 as determined by CAP analysis in 33 patients after 15 weeks of
SCIT injections. The SCIT signiﬁcantly increased antigen-speciﬁc
IgG4 production and the produced IgG4 recognized only the com-
ponents recognized by IgE before the treatment. Patients lacking
IgE reactivity to individual components before SCIT did not produce
speciﬁc IgG4 to the same component or produced negligible
amounts.75 A randomized double-blinded, placebo-controlled,
multicenter phase II/III study for timothy pollinosis also showed no
additional de novo sensitization during short-course SLIT treatment
by CAP analysis of rPhl p 1, rPhl p 5, rPhl p 7, and rPhl p 12.76 The
absence of de novo sensitization during SLIT was also reported in a
study conducted in children with timothy grass pollinosis.77
Considering the results of these studies, the risk of de novo sensi-
tization during SIT using crude extract remains unclear, although
the risk associated with SLIT appears to be low. The induction of IgG
and IgG4 reactive to allergens recognized by IgE prior to treatment
may be a key factor in achieving clinically successful SIT78 (Fig. 2).
Personalized allergen-speciﬁc immunotherapy for Japanese
cedar pollinosis
SIT using modiﬁed Cry j 1 signiﬁcantly improved symptoms for
Japanese cedar pollinosis in patients diagnosed by clinical history
and positive IgE to crude extract of JCP.71,79 Using Cry j 1 will be
sufﬁcient to achieve clinical improvement for Japanese cedar
pollinosis in patients diagnosed more accurately by CRD. For the
patients who do not show clinical improvement using Cry j 1, it will
be considered to be add other allergens for SIT vaccine based of the
information of reactive allergens elucidated by CRD.Conclusions
Although the immunochemical properties of the full spectrum
of the major and important allergens of JCP are not yet fully un-
derstood, the accumulating information on the molecular prop-
erties of these allergens is important in elucidating their crucial
roles in sensitization. The application of this information in com-
bination with molecular biotechnological and immunochemical
techniques will facilitate the preparation of cocktails of allergens
formulated with predetermined and uniform allergen levels. The
availability of these allergens could increase the feasibility of the
development of innovative, patient-based tests for CRD, and
individualized SIT.
In this review, we report the analysis of component allergens
and clinical trials mainly in the context of Japanese cedar pollinosis,
which is a typical type I seasonal allergy for which the causative
allergens are well characterized. In our opinion, Japanese cedar
pollinosis is a good model for the evaluation of novel diagnosis
methods, therapeutic vaccines, and the sensitizing and tolerance-
inducing mechanisms of SIT against the background of genetics
and lifestyle in Japan.Acknowledgment
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